Adherence to antiemetic regimens for patients undergoing emetogenic cancer chemotherapy is poor, according to an online survey of oncology nurses in the United States.

Treating patients with early-stage, resected, node-positive non–small-cell lung cancer with customized chemotherapy based on BRCA1 expression levels did not increase overall survival rates.

This video examines results of a study that looked at treatment tolerability in elderly patients with HPV-positive oropharyngeal squamous cell carcinoma.

Participating in a 12-week physical exercise and psychosocial intervention improved the functional capacity of patients with advanced-stage lung cancer, which may result in improvement in quality of life, according to the results of a study presented at the World Conference on Lung Cancer.

A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.

The FDA has approved the CAR T-cell therapy axicabtagene ciloleucel (Yescarta) for the treatment of large B-cell lymphomas in adults who have failed or relapsed after two or more prior treatments.

The pharmaceutical company AstraZeneca retracted a paper and acknowledged that some preclinical data were falsified regarding its developmental agent acalabrutinib, which is under investigation for use in a number of malignancies.

Small-cell lung cancer patients with high tumor burden treated with immunotherapy had greater objective response rate, progression-free survival, and overall survival compared with patients with medium or low tumor burden.